Your Health, We Care
Release date: 2024-08-08 17:06:45 Recommended: 114
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosine kinase, making it particularly suitable for lung cancer patients with MET14 exon skipping mutations.
Capmatinib has been approved for marketing in China, and according to the drug label, the drug treatment results obtained from the relevant studies are summarized as follows:
Of the 60 patients treated for the first time, 68% had tumors that had shrunk or disappeared. Of these, 5% achieved a complete response (complete tumor disappearance) and 63% achieved a partial response (tumor shrinkage but not complete disappearance); Of the 100 patients who had already received other treatments, 44% had tumor shrinkage, but none achieved a complete response, and all effective responses were partial responses.
The median duration of treatment effect was 16.6 months in patients who were initially treated, and 49% of patients had a response lasting at least 12 months. The median duration of treatment was 9.7 months for patients who had already received other treatments, and 36% of patients had at least 12 months of effect.
Before starting capmatinib, patients should learn more about the precautions for the use of the drug. Regarding the precautions for the use of the drug, the following is a detailed explanation:
During treatment with capmatinib, there is a risk of interstitial lung disease (ILD) or pneumonia. Doctors should closely monitor patients for new or worsening pulmonary symptoms, which may include shortness of breath, cough, or other discomfort. After the diagnosis of ILD or pneumonia, capmatinib should be stopped immediately and should not be continued.
Capmatinib may cause a photosensitization reaction, and the patient's skin may have an abnormal reaction after exposure to sunlight or other ultraviolet light sources. Patients are advised to avoid direct exposure to sunlight as much as possible during treatment, especially during periods of intense sunlight, or to take sun protection measures such as wearing protective clothing or using broad-spectrum sunscreen during outdoor activities.
[Warm tips] Capmatinib has achieved good efficacy in the treatment of clinical diseases, and patients should also pay attention to the possible drug risks during use, and reasonably avoid them by consulting professional doctors.
